🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

545 results for “B.” Clear

  1. NaCl 0,9 % B. Braun, solution injectable, Depo-Medrone 40 mg/ml Suspension for Injection.

    Disc Medicine

    Cluster headache

    phase 3 small molecule active

    1 trial

  2. Natriumklorid B. Braun 9 mg/ml infusjonsvæske, oppløsning, BOTOX 50 Allergan-enheter Pulver til injeksjonsvæske, oppløsning

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic cluster headache

    phase 3 small molecule active

    1 trial

  3. Niraparib Placebo Capsules, Niraparib Placebo Tablets, G5W (5% glucose in water), JEMPERLI 500 mg concentrate for solution for infusion

    TESARO Bio Netherlands B.V.

    Recurrent or primary advanced (Stage III or IV) endometrial cancer

    phase 3 small molecule active

    1 trial

  4. Nucresiran

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis With Cardiomyopathy

    phase 3 small molecule active

    1 trial

  5. Nucresiran

    Alnylam Netherlands B.V.

    Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy

    phase 3 small molecule active

    1 trial

  6. Onpattro 2 mg/mL concentrate for solution for infusion., Sodium Chloride Intravenous Infusion BP 0.9% w/v

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

  7. Open Label Topical Beremagene Geperpavec (B-VEC)

    Krystal Biotech Netherlands B.V.

    Dystrophic Epidermolysis Bullosa

    phase 3 mab completed

    1 trial

  8. PEGCETACOPLAN (APL-2)

    Apellis Europe B.V.

    Geographic Atrophy Secondary to Age-related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  9. PEMBROLIZUMAB

    Ningbo Cancer Hospital

    Patient with early triple-negative breast cancer (TNBC) achieving pathologic complete response (pCR) after neoadjuvant systemic chemotherapy and pembrolizumab.

    phase 3 small molecule active

    1 trial

  10. Patisiran

    Alnylam Netherlands B.V.

    Amyloidosis, Familial

    phase 3 small molecule completed

    1 trial

  11. Patisiran

    Alnylam Netherlands B.V.

    Amyloidosis, Hereditary

    phase 3 small molecule completed

    1 trial

  12. Patisiran

    Alnylam Netherlands B.V.

    Amyloidosis

    phase 3 small molecule completed

    1 trial

  13. Pegcetacoplan

    Apellis Europe B.V.

    PNH

    phase 3 small molecule active

    2 trials

  14. Pegcetacoplan

    Apellis Europe B.V.

    Delayed Graft Function

    phase 3 small molecule active

    1 trial

  15. Pegcetacoplan

    Apellis Europe B.V.

    C3G

    phase 3 small molecule active

    3 trials

  16. Pegcetacoplan

    Apellis Europe B.V.

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule completed

    2 trials

  17. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 3 small molecule completed

    4 trials

  18. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Neuropsychiatric Symptoms Related to Neurodegenerative Disease

    phase 3 small molecule completed

    2 trials

  19. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Irritability Associated With Autism Spectrum Disorder

    phase 3 small molecule completed

    2 trials

  20. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Adjunctive Treatment of Major Depressive Disorder

    phase 3 small molecule terminated

    3 trials

  21. Pimavanserin tartrate (ACP-103)

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease Psychosis

    phase 3 small molecule completed

    4 trials

  22. Placebo

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

    phase 3 small molecule completed

    1 trial

  23. Placebo

    Alnylam Netherlands B.V.

    Primary Hyperoxaluria Type 1 (PH1)

    phase 3 small molecule completed

    1 trial

  24. Placebo

    Agios Netherlands B.V.

    Pyruvate Kinase Deficiency

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources